Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company.
The agreement expands an existing customer relationship and includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. The engagement covers development and clinical manufacturing services for an investigational oncology product, with revenue expected during 2026 and 2027 and stability services extending beyond 2027. Following the agreement, Scinai’s committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million, up 300% from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026.
The deal also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones. To view the full press release, visit https://ibn.fm/5jaNp.
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of more than 75 brands within the Dynamic Brand Portfolio at IBN that delivers access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
For more information, visit www.MissionIR.com. Full terms of use and disclaimers are available at https://www.MissionIR.com/Disclaimer.
